Addition of Aspirin to Standard of Care in Oral Cancer
Status:
Not yet recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
Despite accumulating evidence of the benefit of aspirin in cancer, its effect on improving
cancer survival is still debated since the mechanism by which it impacts cancer survival is
not completely understood and the published data are discordant. There have been 4 randomized
controlled trials (RCT) showing mixed results from no effect to improved survival. Several
retrospective and observational studies have reported a survival advantage of adding aspirin
to the treatment for various cancers. A meta-analysis of 118 studies, 63 of them specifically
reporting on cancer mortality and the rest on all-cause mortality, found a 21% reduction in
cancer deaths and about 20% reduction in all-cause mortality (pooled hazard ratio (HR): 0.79;
95% confidence intervals: 0.73, 0.84).
However, the evidence is still lacking and there is need to do more RCT